Neos Therapeutics (NEOS) Posts Wider-than-Expected Q2 Loss

Neos Therapeutics (NASDAQ: NEOS) reported Q2 EPS of ($7.76), $3.45 worse than the analyst estimate of ($4.31). Revenue for the quarter came in at $1.48 million versus the consensus estimate of $1.7 million.

For earnings history and earnings-related data on Neos Therapeutics (NEOS) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Range Impact, Inc. (RNGE) Reports Q2 Loss of $0.02
• Candel Therapeutics, Inc. (CADL) Misses Q2 EPS by 29c